Vaccine Development

Vaccine Development Vaccines Infectious Diseases Public Health Regulatory Affairs Vaccines COVID-19 Immunology FDA Clinical Trials

3 ARTICLES

last wk.

FDA approves Moderna’s mNEXSPIKE vaccine for seniors and high-risk Americans

Phase 3 data showed the new booster provided stronger protection than Moderna’s original shot, with distribution set for the 2025–2026 respiratory season.

30 ARTICLES

last wk.

Vaxart's Oral Norovirus Vaccine Shows Promise in Early Trials for Elderly Adults

4 ARTICLES

3mo ago

Scientists Identify New Coronavirus in Bats Capable of Infecting Humans

9 ARTICLES

4mo ago

AstraZeneca Cancels £450m UK Vaccine Plant Investment

Vaccine Development

FDA approves Moderna’s mNEXSPIKE vaccine for seniors and high-risk Americans

HHS Withdraws $766 Million From Moderna’s Bird Flu Vaccine Program

Moderna Withdraws Flu-COVID Vaccine Application After FDA Requests More Data

FDA Grants Limited Approval to Novavax’s COVID-19 Vaccine

Vaxart's Oral Norovirus Vaccine Shows Promise in Early Trials for Elderly Adults

Scientists Identify New Coronavirus in Bats Capable of Infecting Humans

AstraZeneca Cancels £450m UK Vaccine Plant Investment